1. 1662TiPVOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST). (23rd October 2018) Authors: Bauer, S; George, S; Kang, Y-K; Tap, W D; Zhou, T; Picazio, N; Boral, A L; Heinrich, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-197VOYAGER: an open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour. (2nd July 2019) Authors: Bauer, S; George, S; Kang, Y; Jones, R; Mir, O; Tap, W; Doyle, A; Picazio, N; Zhou, T; Roche, M; Heinrich, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗